Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Resonance Health Ltd ( (AU:RHT) ) has provided an update.
Resonance Health Ltd has announced an investor strategy day, inviting stakeholders to join a live webcast hosted by key company executives. The event aims to provide insights into the company’s strategic direction and will be available for later viewing. This initiative underscores Resonance Health’s commitment to transparency and engagement with its stakeholders, potentially strengthening its market position and fostering investor confidence.
More about Resonance Health Ltd
Resonance Health is an Australian healthcare technology and services company that provides globally recognized quantitative assessments for disease management and drug development. The company has achieved regulatory clearances for its Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and holds ISO 13485 certification. Its products, which include FerriScan®, FerriSmart®, HepaFatScan®, HepaFatSmart®, LiverSmart®, and CardiacT2*, are used in non-invasive MRI-based assessments for conditions like iron overload and fatty liver disease.
Average Trading Volume: 396,085
Technical Sentiment Signal: Sell
Current Market Cap: A$19.77M
Learn more about RHT stock on TipRanks’ Stock Analysis page.